Although we were initially drawn to PBDs due to their insensitivity to P-glycoprotein-mediated drug efflux and their ability to kill both CD276+ tumor vasculature and cancer cells,14 they also display potent bystander killing, helping to ensure killing of target-negative cells in cases where CD276 expression on tumor cells is heterogeneous. The gene discussed is CD276; the disease is cancer.